The 340B program was discussed at length today during a U.S. House subcommittee hearing on price transparency and consolidation in health care, with three Republicans questioning whether hospitals are abusing the program and two Democrats and a Republican cautioning against
…
Ryan White Clinics for 340B Access has announced it opposes the drug industry’s joint plan with community health centers to restructure the 340B program, saying it will increase manufacturers’ “already astronomical profits at the expense of safety net providers.”
Hemophilia
…
Biopharmaceutical company Dermavant Sciences is giving refunds to health care providers that paid above the 340B ceiling price for Vtama, a non-steroidal cream to treat plaque psoriasis.
The U.S. Health Resources and Services Administration posted Dermavant’s notice to 340B covered
…
A confidential document composed by Pharmaceutical Research and Manufacturers of America in connection with its 340B program reform initiative with the National Association of Community Health Centers fleshes out a “coalition” vision of the 10-point reform plan that the two
…
The fallout continues from drug makers and health centers’ decision to work together to change the 340B program, with the drug industry giving its first interview about the deal to 340B Report on Friday and several hospital groups jointly blasting
…
The second quarterly period this year for 340B registration of new covered entities, outpatient facilities, and contract pharmacies will begin Saturday, April 1, and is expected to end on Monday, April 17.
Normally, a quarterly 340B registration period runs from
…
U.S. House Republicans yesterday asked Department of Health and Human Services Secretary Xavier Becerra to testify March 29 about the Biden administration’s health care budget request.
Becerra will appear before the Energy & Commerce health subcommittee the day after it
…
Congressional Medicare advisers yesterday formally recommended replacing the formula Medicare uses to distribute extra payments to safety net hospitals that disproportionately serve low-income and/or uninsured beneficiaries.
The 340B program uses the same calculation—the Medicare disproportionate share adjustment percentage—to determine eligibility
…
The U.S. Centers for Medicare & Medicaid Services Tuesday announced the first 27 prescription drugs that will be subject to Medicare Part B inflation rebates, a list that includes AbbVie’s blockbuster arthritis drug Humira, which generated $5.6 billion in global
…*Sign up for news summaries and alerts from 340B Report